Local Salvage Treatment of Post-brachytherapy Recurrent Prostate Cancer via Theranostic Application of PSMA-labeled Lutetium-177
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 16 (2) , 99-102
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancerOncotarget, 2016
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and EfficacyJournal of Nuclear Medicine, 2016
- 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human StudiesJournal of Nuclear Medicine, 2015
- [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Underutilization of local salvage therapy after radiation therapy for prostate cancerUrologic Oncology: Seminars and Original Investigations, 2014
- Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Role of focal salvage ablative therapy in localised radiorecurrent prostate cancerWorld Journal of Urology, 2013
- External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised studyThe Lancet Oncology, 2010
- Treatment failure after primary and salvage therapy for prostate cancerCancer, 2007
- LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMYUrologic Clinics of North America, 2001